A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers
Study of Intratumorally Administered INT230-6 in Adult Subjects with Solid Tumors
Sponsor: Intensity Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAS1193
U.S. Govt. ID: NCT03058289
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to determine the safety of administering an investigational new drug (referred to as INT230-6 or the study drug) directly into multiple superficial (you can feel them with touch) and deep tumors (such as those within the body or inside an organ e.g. the liver). Investigational means that INT230-6 has not yet been approved by regulatory authorities such as the United States Food and Drug Administration (FDA) or Health Canada for use outside of clinical trials. This drug has not been given to humans prior to this study. Cancer types include: breast cancer, liver cancer, colon cancer, rectal cancer, lung cancer, and melanoma.
This study is closed
Matthew Ingham, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a solid tumor (listed in description)? Yes No
Does your cancer continue to grow despite treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator